DE69726672T2 - Polyätherester-Copolymere als Matrixmaterialien für die Arzneistoffabgabe - Google Patents

Polyätherester-Copolymere als Matrixmaterialien für die Arzneistoffabgabe Download PDF

Info

Publication number
DE69726672T2
DE69726672T2 DE69726672T DE69726672T DE69726672T2 DE 69726672 T2 DE69726672 T2 DE 69726672T2 DE 69726672 T DE69726672 T DE 69726672T DE 69726672 T DE69726672 T DE 69726672T DE 69726672 T2 DE69726672 T2 DE 69726672T2
Authority
DE
Germany
Prior art keywords
drug delivery
matrix materials
polyetherester copolymers
polyetherester
glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69726672T
Other languages
English (en)
Other versions
DE69726672D1 (de
Inventor
Jacob Hillebrand Goedemoed
Wilhelmus Everhardus Hennink
Jeroen Mattijs Bezemer
Jan Feijen
Blitterswijk Clemens Anton Van
Bruijn Joost Dick De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octoplus Polyactive Sciences Bv Leiden Nl
OctoPlus Sciences BV
Biolex Therapeutics Inc
Original Assignee
Chienna BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chienna BV filed Critical Chienna BV
Application granted granted Critical
Publication of DE69726672D1 publication Critical patent/DE69726672D1/de
Publication of DE69726672T2 publication Critical patent/DE69726672T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69726672T 1996-08-16 1997-08-18 Polyätherester-Copolymere als Matrixmaterialien für die Arzneistoffabgabe Expired - Lifetime DE69726672T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/699,896 US5980948A (en) 1996-08-16 1996-08-16 Polyetherester copolymers as drug delivery matrices

Publications (2)

Publication Number Publication Date
DE69726672D1 DE69726672D1 (de) 2004-01-22
DE69726672T2 true DE69726672T2 (de) 2004-10-07

Family

ID=24811379

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69729228T Expired - Lifetime DE69729228T2 (de) 1996-08-16 1997-08-18 Polyetherester-Copolymere als Matrixmaterial für die Arzneistoffabgabe
DE69726672T Expired - Lifetime DE69726672T2 (de) 1996-08-16 1997-08-18 Polyätherester-Copolymere als Matrixmaterialien für die Arzneistoffabgabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69729228T Expired - Lifetime DE69729228T2 (de) 1996-08-16 1997-08-18 Polyetherester-Copolymere als Matrixmaterial für die Arzneistoffabgabe

Country Status (9)

Country Link
US (1) US5980948A (de)
EP (2) EP1247522B1 (de)
AT (2) ATE255884T1 (de)
CA (1) CA2213368C (de)
DE (2) DE69729228T2 (de)
DK (2) DK0830859T3 (de)
ES (2) ES2212037T3 (de)
PT (2) PT830859E (de)
WO (1) WO1998006439A1 (de)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842657A1 (de) * 1996-11-19 1998-05-20 OctoPlus B.V. Mikrosphären zur gesteuerten Freisetzung und Verfahren zur Herstellung dieser Mikrosphären
FR2777895A1 (fr) * 1998-04-28 1999-10-29 Debio Rech Pharma Sa Polymere sequence non-reticule,procede pour sa preparation, et ses utilisations
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6656489B1 (en) 1999-02-10 2003-12-02 Isotis N.V. Scaffold for tissue engineering cartilage having outer surface layers of copolymer and ceramic material
EP1038538A1 (de) * 1999-03-19 2000-09-27 IsoTis B.V. Verfahren zur Regeneration von Muskelgewebe
EP1173151B1 (de) 1999-04-16 2003-07-09 Novo Nordisk A/S Trockene formbare arzneistoffformulierung
EP1068872A1 (de) * 1999-07-12 2001-01-17 IsoTis B.V. Nahtmaterialen
JP2001054563A (ja) * 1999-07-12 2001-02-27 Isotis Bv 縫合糸
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
DE60043630D1 (de) * 1999-08-06 2010-02-11 Chienna Bv Formung eines Polymers
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
EP1090928B1 (de) * 1999-09-30 2004-05-26 Chienna B.V. Mit bioaktiven Mitteln beladene Polymeren
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
DE60127139T2 (de) * 2000-07-14 2007-12-13 Novo Nordisk A/S Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
EP1247537A1 (de) * 2001-04-04 2002-10-09 Isotis B.V. Beschichtung für medizinische Vorrichtungen
US6565884B2 (en) 2001-09-10 2003-05-20 Interpore Cross International Bone graft material incorporating demineralized bone matrix and lipids
US7357947B2 (en) * 2001-09-10 2008-04-15 Biomet, Inc. Bone graft material incorporating demineralized bone matrix and lipids
JP2005510521A (ja) * 2001-11-12 2005-04-21 アルカーメス コントロールド セラピューティクス，インコーポレイテッド 生体適合性ポリマーブレンドおよびその使用
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
WO2003072631A1 (en) * 2002-02-26 2003-09-04 Chienna B.V. Biodegradable polymeric material for biomedical applications
EP1509182A4 (de) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc Implantierbare polymere vorrichtung zur verzögerten freisetzung von buprenorphin
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6926919B1 (en) * 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
CN1777426A (zh) * 2003-03-31 2006-05-24 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
US20040215318A1 (en) * 2003-04-24 2004-10-28 Brian Kwitkin Timed delivery of therapeutics to blood vessels
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
WO2005094553A2 (en) 2004-03-24 2005-10-13 Doctor's Research Group, Inc. Compositions for promoting bone growth and methods thereof
EP2329852A1 (de) 2004-03-26 2011-06-08 SurModics, Inc. Zusammensetzung und Verfahren zur Herstellung von biokompatiblen Oberflächen
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
KR20070039593A (ko) 2004-07-21 2007-04-12 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
US7311980B1 (en) * 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0426822D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
ATE541934T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
MX2007007580A (es) 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
BRPI0518661A2 (pt) * 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20060147491A1 (en) * 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
EP1679065A1 (de) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
EP1893229B1 (de) * 2005-06-03 2011-10-19 Ambrx, Inc. Verbesserte humane interferon-moleküle und ihre verwendungen
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
AU2006311568B2 (en) * 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
PT2339014E (pt) * 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
JP5401095B2 (ja) 2005-11-17 2014-01-29 ゾゲニクス インコーポレーティッド 無針注射による粘性製剤の送達方法
EP1968635B1 (de) * 2005-12-14 2014-09-17 Ambrx, Inc. Zusammensetzungen und Verfahren mit und Verwendung von nicht-natürlichen Aminosäuren und Polypeptiden
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
JP2009542671A (ja) * 2006-06-28 2009-12-03 サーモディクス，インコーポレイティド 微粒子を含む活性剤溶出マトリックス
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
US8420792B2 (en) * 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
CA2662753C (en) * 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
US20080154241A1 (en) * 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
EP2068909B1 (de) 2007-03-30 2012-04-25 Ambrx, Inc. Modifizierte fgf-21 polypeptide und ihre verwendung
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
AU2008256819A1 (en) 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
WO2009005718A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles having sustained release characteristics, methods and uses
WO2009005709A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles
US8137661B2 (en) * 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US9138509B2 (en) * 2007-09-14 2015-09-22 Musculoskeletal Transplant Foundation Composition for filling bone defects
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
EP2055299A1 (de) 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Verfahren zur Herstellung von Polymermikropartikeln
ES2709120T3 (es) 2007-11-16 2019-04-15 Aclaris Therapeutics Inc Composiciones y métodos para tratar la púrpura
JP5547083B2 (ja) * 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
DE102007062113B4 (de) * 2007-12-21 2011-05-12 Bettina Lingenfelder Dermatologische Zubereitung
CN101946043B (zh) * 2007-12-21 2013-08-07 3M创新有限公司 回射道路标记
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
JP2011509944A (ja) * 2008-01-14 2011-03-31 サーモディクス，インコーポレイティド 核酸送達複合体の溶出のための装置及び方法
JP5667559B2 (ja) 2008-03-28 2015-02-12 サーモディクス，インコーポレイティド 微粒子が配置された弾性基質を有する挿入可能な医療機器、および薬物送達方法
US20090263449A1 (en) * 2008-04-09 2009-10-22 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
US8496954B2 (en) * 2008-04-18 2013-07-30 Surmodics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
EP2756756B1 (de) 2008-04-28 2016-01-06 Zogenix, Inc. Neuartige Formulierungen zur Behandlung von Migräne
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
WO2010009122A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
JP5722217B2 (ja) 2008-09-02 2015-05-20 アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｈｏｌｄｉｎｇｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用
WO2010031007A2 (en) 2008-09-12 2010-03-18 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
US8883208B2 (en) * 2009-04-08 2014-11-11 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
WO2010118238A2 (en) * 2009-04-08 2010-10-14 Surmodics, Inc. Controlled release devices and methods for delivery of nucleic acids
US8246576B2 (en) 2009-05-18 2012-08-21 Surmodics, Inc. Method and apparatus for delivery of a therapeutic agent with an expandable medical device
AU2010341516B2 (en) 2009-12-21 2014-01-16 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
WO2011110894A2 (en) 2010-03-12 2011-09-15 Allergan Industrie Sas Fluid composition for improving skin conditions
HUE043344T2 (hu) 2010-03-22 2019-08-28 Allergan Inc Térhálósított hidrogélek lágy szövet növelésére
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
CA2804601C (en) 2010-07-09 2020-05-19 Innocore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
US20120100187A1 (en) 2010-10-26 2012-04-26 Surmodics, Inc. Coatings and methods for controlled elution of hydrophilic active agents
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
FR2975301B1 (fr) 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
KR102015676B1 (ko) 2011-06-03 2019-10-21 알러간, 인코포레이티드 항산화제를 포함하는 피부 충전제 조성물
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
EP2734573B1 (de) 2011-07-22 2021-09-08 InnoCore Technologies Holding B.V. Phasensengetrennte segmentierte mehrblockcopolymere und freisetzung von biologisch aktiven substanzen
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
SI3584255T1 (sl) 2012-08-31 2022-05-31 Sutro Biopharma, Inc Modificirane aminokisline, ki vsebujejo azido skupino
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
JP6438406B2 (ja) 2012-11-05 2018-12-12 サーモディクス，インコーポレイテッド 疎水性生理活性物質を送達するための組成物および方法
WO2014167440A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
CA2913155A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
FR3007972B1 (fr) 2013-07-04 2015-08-07 Oreal Composition cosmetique comprenant des esters gras liquides, des huiles volatiles et des epaississants, et procede de traitement cosmetique
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
WO2015150948A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
EP3191593A4 (de) 2014-09-08 2018-01-24 University of Iowa Research Foundation Mikrorna-hemmersystem und verfahren zur verwendung davon
EP3620184A1 (de) 2014-09-30 2020-03-11 Allergan Industrie, SAS Stabile hydrogelzusammensetzungen mit additiven
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AU2018389104A1 (en) 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
CA3111576A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP3867265A1 (de) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5066772A (en) * 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
FR2671562B1 (fr) * 1991-01-16 1995-09-15 Oreal Procede de diagnostic d'un etat d'inflammation ou de vieillissement cellulaire des keratinocytes, et necessaire pour la mise en óoeuvre de ce procede.
PT627911E (pt) * 1992-02-28 2001-04-30 Univ Texas Hidrogeis biodegradaveis fotopolimerizaveis como materiais de contacto de tecidos e veiculos de libertacao controlada
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
EP0637229B1 (de) * 1992-04-24 2002-11-20 Osteotech, Inc., Vorrichtung zum vermeiden von gewebeadhäsionen
DE69305313T3 (de) * 1992-12-22 2001-06-21 Univ Cincinnati Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen
CA2167081A1 (en) * 1993-07-12 1995-01-26 Alexander K. Andrianov Hydrogel microencapsulated vaccines
ES2171186T3 (es) * 1994-04-08 2002-09-01 Atrix Lab Inc Composiciones liquidas de difusion.
EP0717999A1 (de) * 1994-12-19 1996-06-26 The University Of Miami Zusammensetzung zur Arzneistoffabgabe

Also Published As

Publication number Publication date
DE69729228T2 (de) 2005-05-04
EP1247522A1 (de) 2002-10-09
PT1247522E (pt) 2004-10-29
ATE255884T1 (de) 2003-12-15
CA2213368C (en) 2008-04-01
ATE267006T1 (de) 2004-06-15
ES2212037T3 (es) 2004-07-16
WO1998006439A1 (en) 1998-02-19
EP0830859B1 (de) 2003-12-10
EP0830859A3 (de) 1998-07-22
US5980948A (en) 1999-11-09
DK1247522T3 (da) 2004-09-27
DK0830859T3 (da) 2004-04-05
CA2213368A1 (en) 1998-02-16
ES2221916T3 (es) 2005-01-16
PT830859E (pt) 2004-04-30
EP1247522B1 (de) 2004-05-19
DE69729228D1 (de) 2004-06-24
DE69726672D1 (de) 2004-01-22
EP0830859A2 (de) 1998-03-25

Similar Documents

Publication Publication Date Title
ATE255884T1 (de) Polyätherester-copolymere als matrixmaterialien für die arzneistoffabgabe
CA2304976A1 (en) Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
CA2355657A1 (en) Biodegradable ph/thermosensitive hydrogels for sustained delivery of biologically active agents
ZA9811377B (en) Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
CA2289088A1 (en) Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream
EP2260872A3 (de) Polymer-Konjugate von Interferon beta-1A und ihre Verwendungen
ATE241377T1 (de) Pharmazeutische zusammensetzungen für die verzögerte freisetzung von peptiden und verfahren zu deren herstellung
HUP0500108A2 (en) Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DE3786309T2 (de) Alkylenoxydblöcke enthaltende Polyester und deren Verwendung als Arzneimittelabgabesysteme.
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
WO2003091337A8 (en) New polyarylates for drug delivery and tissue engineering
HUP0102803A2 (hu) Hőérzékeny és biológiailag lebontható hidrogélek biológiailag aktív anyagok elnyújtott idejű felszabadulásának biztosítására
ZA200204603B (en) Amphiphilic polymers and polypeptide conjugates comprising same.
EE200000219A (et) Kõnepostkast GSM-süsteemis
HUP0001458A3 (en) Specific pancreatic lipase inhibitor peptides, pharmaceutical compositions and diagnostical reagents comprising thereof and their applications
CA2273272A1 (en) Immediate release drug delivery forms
AU2002251955A1 (en) Biodegradable cationic copolymers of poly(alkylenimine) and poly(ethylene glycol) for the delivery of bioactive agents
ATE90952T1 (de) Alkylenoxydbloecke enthaltende polyester und deren verwendung als arzneimittelabgabesysteme.
ES1037874Y (es) Dispositivo de carga y descarga horizontal.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOLEX THERAPEUTICS, INC., PITTSBORO, N.C., US

Owner name: OCTOPLUS POLYACTIVE SCIENCES B.V., LEIDEN, NL

Owner name: OCTOPLUS SCIENCES B.V., LEIDEN, NL